EQT Withdraws Takeover Bid for Oxford Biomedica; Shares Plunge 10%

Key Facts

Private equity firm EQT has officially decided not to proceed with its potential takeover bid for Oxford Biomedica, a UK-based cell and gene therapy manufacturer. The announcement led to a sharp decline in Oxford Biomedica's stock price, which fell nearly 10% following the news. While EQT did not disclose specific strategic reasons for the withdrawal, the move ends weeks of speculation regarding a possible acquisition. The cancellation of the bid has effectively removed the acquisition premium from the stock price, triggering a significant sell-off. Analysts suggest that Oxford Biomedica must now navigate its future growth strategy as an independent entity in the competitive biotech sector. This development highlights the ongoing volatility and uncertainty in the M&A landscape within the British healthcare market.